Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...

The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...

Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...

Key Takeaways A patient died from liver injury while taking the gene therapy ElevidysSarepta says more than 800 patients have ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...

Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Genetic medicine firm Sarepta Therapeutics announced the tragic death of a young man with Duchenne muscular dystrophy (DMD) ...

The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the ...